Abstract Establishing
Introduction
In the field of pharmacokinetics, many kinds of screening methods for the evaluation of the absorption, distribution, metabolism, and excretion (ADME) properties have been established. However, it is still necessary to develop and improve methods with which drug exposure in several tissues (especially pharmacological and toxicological targets) can be predicted by integrating the results of in vitro and in vivo studies. For the rational selection of candidate compounds, it is essential to carry out quantitative analyses based on a pharmacokinetic/pharmacodynamic (PK/PD) model ( Fig. 1 ) RostamiHodjegan and Tucker 2007) . Ideally, PK/PD modeling must be associated with an in silico screening that allows us to predict the ADME properties of drugs solely from their chemical structures. These kinds of approaches enable us to establish a so-called value-added library in which compounds that are predicted to exhibit undesirable pharmacokinetic properties judging from several assays were not included, which may accelerate the throughput of drug discovery and development (Sugiyama 2005; RostamiHodjegan and Tucker 2007) .
For example, pravastatin, a 3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase inhibitor used for the treatment of hyperlipidemia, undergoes gastrointestinal absorption, hepatic uptake, and biliary excretion from the liver to the bile, and some transporters are known to be involved in all of these processes (although this is still controversial regarding gastrointestinal absorption). In this case, the efficient hepatic uptake makes it possible to accumulate pravastatin in the liver, which is the pharmacological target of HMGCoA reductase inhibitors, and to minimize its appearance in the systemic blood. These pharmacokinetic properties supported by the functions of transporters greatly contribute to the optimization of both pharmacological (cholesterollowering) and adverse effects (i.e., rhabdomyolysis) of pravastatin ( Fig. 2) . In this case, the involvement of transporters in the overall disposition and elimination of pravastatin was clarified after coming on the market. If the transport and metabolic properties of candidate drugs can be easily evaluated with appropriate experimental systems and prediction methods from in vitro analyses, the strategic development of drugs with good pharmacokinetic properties in the preclinical screening stage should be possible in the near future.
Prediction of in vivo pharmacokinetics in humans from in vitro experiments
The importance of drug transporters as factors in determining drug efficacy and adverse effect of drugs has recently been recognized, and a chapter is devoted to drug transporters in the latest (11th) edition of the textbook of pharmacology, Goodman and Gilman's The Pharmacological Basis of Therapeutics (Giacomini and Sugiyama 2005) . Many uptake and efflux transporters which play important roles in the drug disposition in the liver, kidney, intestine, and brain have been identified, although not all of their significance has been quantitatively analyzed yet (Fig. 3) (Petzinger and Geyer 2006) . To apply this in vitro information (substrate specificity, etc.) to the development and proper use of drugs, it is important to establish and validate the methodologies for the prediction of in vivo human pharmacokinetic parameters from in vitro experiments. Now many in vitro tools are available such as Caco-2 cells (for gastrointestinal absorption), cryopreserved human hepatocytes, sandwichcultured human hepatocytes, human kidney slices, or transporter-expressing cell lines, and the prediction methods of human pharmacokinetics from in vitro studies are urgently needed. In the field of metabolic enzymes, it is possible to directly estimate the in vivo hepatic metabolic clearance in individual persons using the appropriate probe drugs for each isoform of the cytochrome P450 enzyme (i.e., midazolam for CYP3A4, warfarin for CYP2C9) by measuring the time profile of plasma concentration of the parent drug and its metabolites and their amounts excreted into the urine (Frye et al. 1997; Chainuvati et al. 2003; Tanaka et al. 2003) . Similarly, to estimate the in vivo functions of hepatic and/or renal transporters, it is necessary to search for a "probe drug" that is taken up into and/or excreted from each tissue via a specific transporter and whose pharmacokinetics is sensitively influenced by the change in the function of single transporter, although it is not easy to search for a "probe drug" which can be used in the clinical situations because of the overlapping substrate specificity. However, practically, it is allowable to use ligands which are transported predominantly by single transporter in each human organ, although they are recognized by multiple transporters in in vitro transport assay. The contribution of specific transporter to the overall membrane transport of ligands can be evaluated by using several methods (Maeda and Sugiyama 2007) . In the case of transporters in the brain, we must measure the drug efficacy or use a probe for positron emission tomography (PET) to evaluate the distribution of the drug to the brain (discussed below) because the volume of the brain is too small to show any changes in the plasma concentrations of the drug produced by functional changes in its transporters.
Extrapolation of human pharmacokinetics from in vitro data and in vivo animal data
Generally, it is difficult to directly extrapolate the results obtained from animal studies in vivo to human pharmacokinetics because there are sometimes large species differences in the functions and expression levels of enzymes and transporters. For example, coadministration of probenecid with famotidine results in the decrease in the renal clearance of famotidine in humans, but not in rats. Famotidine is taken up into kidney mainly by Oct1 and Oct2 in rats and the contribution of Oat3 to its uptake is smaller than that in humans. On the other hand, in humans, OAT3 mainly mediates the uptake of famotidine. Therefore, OAT3-mediated transport of famotidine is inhibited by probenecid in humans, while in rats, Oat3-mediated transport is minor and Oct-mediated transport is not After the oral administration of pravastatin, it is absorbed from the intestinal lumen by passive diffusion and/or active transport mediated by OATP family transporters (still controversial), followed by its hepatic uptake and biliary excretion by OATP1B1 and MRP2, respectively. This series of transporter-mediated transport processes plays an important role in the efficient enterohepatic circulation of pravastatin. The enterohepatic circulation increases the exposure of pravastatin in the target tissue (liver) leading to the increase in pharmacological effect, and the efficient hepatic uptake minimizes the escape of the drug into the circulating blood during the first-pass extraction in the liver leading to the minimal side effect such as rhabdomyolysis inhibited by probenecid (Tahara et al. 2005a ). Thus, the clinical drug-drug interaction between famotidine and probenecid observed in humans cannot be reproduced in rats. Then, the relative clearances of nine substrates mediated by human OAT3 did not correlate well with those mediated by rat Oat3, suggesting the species difference in the rank order of transport activity of ligands (Tahara et al. 2005b) . It is also difficult to validate the predicted human values, especially in the case of transporters, because there is limited information available on these parameters. To overcome these problems, we will perform pharmacokinetic studies in vitro and in vivo using some kinds of animals (i.e., rat, dog, and monkey) and integrate the results using an appropriate mathematical pharmacokinetic model. If the model for each animal is well-validated, it is likely that this model can also be applied to humans. Then, we perform an in vitro study using human tissues and transporter/enzyme expression systems to predict the human pharmacokinetics in vivo using the mathematical model constructed for animal.
Successful examples have been reported to predict the observed oral clearance (oral administered dose divided by AUC 0-inf in blood) in vivo in humans of eight different compounds from in vitro results by multiplying the scaling factor (the ratio of the metabolic intrinsic clearance in vivo in intact animals to the metabolic clearance in vitro in microsomes from the same animal species) by the in vitro metabolic clearance estimated from human samples with appropriate mathematical models that describe hepatic elimination (well-stirred, parallel-tube, and dispersion models) (Naritomi et al. 2001 ).
Tissue-specific distribution and toxicity mediated by transporters
Attention should be given to the transporter-mediated pharmacokinetic properties of drugs from the viewpoint of tissue toxicity. For example, active uptake in a specific tissue may result in tissue-selective toxicity. Metformin (one of the biguanides) is widely used for the treatment of type 2 diabetes, but lactic acidosis is known to be a serious adverse effect. We investigated the involvement of organic cation transporters (OCTs) in the pharmacokinetics and hepatic accumulation of metformin. We found that biguanides are substrates of OCT1 involved in its hepatic uptake (Wang et al. 2002) and that metformin-induced lactic acidosis is repressed in Oct1 knockout mice (Wang et al. 2003) (Fig. 4) , indicating that the liver is the target organ for its toxicity. Thus, the biguanides with fewer side effects are expected to be developed by modifying the substrate recognition properties of transporters-ideal biguanides will be recognized more by OCT2 in the kidney and much less by OCT1 in the liver.
In the case of the blood-brain barrier, the distribution of many compounds into the brain is restricted because the compounds are actively pumped out from the brain capillary endothelial cells into the blood by several efflux transporters, such as P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) (Schinkel et al. 1996; Breedveld et al. 2005; Enokizono et al. 2007) . It has also been demonstrated that the organic anion transporting polypeptide (OATP) family and the organic anion transporter (OAT) family transporters are involved in the brain efflux of relatively hydrophobic and hydrophilic organic anions, respectively, using inhibitors of these transporters . They are considered to play roles in the uptake of drugs from the interstitial space in the brain to brain endothelial cells, the first step in the efflux from the brain to the blood. Interindividual variability in the functions of efflux transporters may cause the difference in the concentrations of drugs in the brain and subsequent drug efficacy and/or adverse effect at the brain. In the near future, we expect that clinical studies using PET will be performed to directly analyze the functions of brain transporters in humans. Studies using monkeys have shown that the brain distribution of [ 11 C]-verapamil, a probe drug for P-gp, increased in the presence of PSC833, a P-gp inhibitor (Fig. 5) . PET has been already used in humans to evaluate the drug-drug interaction and effects of single nucleotide polymorphisms (SNPs) of human multidrug resistance protein 1 (MDR1) in the brain (Brunner et al. 2005; Sasongko et al. 2006; Takano et al. 2006 ).
Optimization of pharmacokinetics by control of elimination
The control of clearance (hepatic and renal elimination) is thought to be one of the best strategies for avoiding adverse effects. The transporter-mediated uptake and efflux of drugs in the liver and kidney and their metabolism in the liver are the main factors governing the clearance pathway from the circulating blood. Many kinds of transporters are localized in the basolateral and apical membranes of the liver and kidney and involved in the elimination of drugs from the blood to the bile or urine . Therefore, control of the clearance pathway should be possible by controlling the interaction of drugs with these transporters. For example, although many kinds of angiotensin-converting enzyme (ACE) inhibitors, such as enalaprilat and captopril, are excreted preferentially in the urine, temocaprilat (the active form of its prodrug, temocapril) is excreted in the bile and urine to the similar extent. Temocaprilat is a substrate of multidrug resistance-associated protein 2 (MRP2), whereas other ACE inhibitors are not good substrates of MRP2 (Ishizuka et al. 1997) . Consequently, only temocaprilat undergoes biliary excretion mediated by MRP2 in humans (Fig. 6 ) and the pharmacokinetics of temocaprilat is not altered in patients with renal failure as much as the pharmacokinetics of other ACE inhibitors (Oguchi et al. 1993) (Fig. 6) . In the future, because the number of drugs whose pharmacokinetics is governed by transporters has been rapidly increased, greater care must be taken to balance the clearance pathway, as described above.
A new in vitro tool to mimic the transcellular transport mediated by uptake and efflux transportersthe "double transfectant"
The "double transfectant" is a good tool for screening the transcellular transport of drugs mediated by uptake and efflux transporters in various tissues. In the double transfectant, the transporter involved in the uptake of drugs from the blood to the cells is expressed on the basal membrane and the transporter involved in the excretion of drugs from the hepatocytes is expressed on the apical membrane. We have constructed a set of double transfectants in which OATP1B1 is expressed on the basal membrane and MRP2, MDR1, or BCRP is simultaneously expressed on the apical membrane of polarized MDCKII cells, as an in vitro model of hepatobiliary excretion (Sasaki et al. 2002; Matsushima et al. 2005) (Fig. 7) . Independently, Prof. Keppler's group has established OATP1B3/MRP2 double-transfected cells (Cui et al. 2001; Letschert et al. 2005 ) and quadruple-transfected cells expressing OATP1B1, OATP1B3, OATP2B1, and MRP2, which can enable us to easily identify the organic anions which are substrates of MRP2 (Kopplow et al. 2005) . Moreover, as a model of the transcellular transport of organic cations in the liver, they have also constructed the OCT1/ MDR1 double-transfected cells and observed the transcellular transport of berberine (Nies et al. 2008 ). Using these cell lines, the transporters involved in the hepatobiliary transport of several clinically important drugs have been identified Matsushima et al. 2005; Yamashiro et al. 2006) (Fig. 7) .
Furthermore, a method to evaluate the contribution of each efflux transporter to biliary excretion across the human canalicular membrane of hepatocytes should be developed in the future. Sasaki et al. have demonstrated that in vivo biliary excretion clearance of several compounds in rats was well predicted from their in vitro transcellular transport clearance in an Oatp1b2/Mrp2 double transfectant (rat isoforms corresponding to human OATP1B1/OATP1B3 on the basal membrane and MRP2 on the apical membrane) (Sasaki et al. 2004) . Therefore, the transport of drugs from the blood to the bile in humans will also be predictable in the future by evaluating the in vitro transcellular transport in a human double transfectant with appropriate scaling factor which relates the in vivo hepatic intrinsic clearance to the in vitro transcellular transport clearance. control +PSC833 (P-gp inhibitor) (A) (B) Fig. 6 Mechanism determining the difference in the pharmacokinetics of ACE inhibitors and its impact on clinical pharmacokinetics (effect of renal dysfunction on the plasma concentration of these drugs). a Temocaprilat (an active metabolite of its prodrug, temocapril) undergoes biliary excretion by MRP2 and it is cleared from both urine and bile, whereas other ACE inhibitors such as enalaprilat (an active metabolite of enalapril) and captopril are not good substrates of MRP2 and, thus, they are mainly excreted in the urine. b In patients with renal failure, the plasma concentration of enalaprilat dramatically increased, whereas that of temocaprilat did not increase so much. CLcr represents creatinine clearance, generally used as a marker of the glomerular filtration rate in the kidney. b is reproduced with permission from Oguchi et al. 1993 To predict the biliary excretion clearance of organic anions mediated by each efflux transporter and the contribution of each transporter to their overall biliary efflux in humans from in vitro data, the following strategy can be applied (Fig. 8) . Using a set of double-transfected cells, the efflux clearance from intracellular compartment across the apical membrane (PS apical,transporter ) of ligands in each double transfectant can be calculated by dividing the velocity of basal-to-apical transcellular transport by intracellular concentration of ligands at steady state. We can also estimate the relative expression level of MRP2, MDR1, and BCRP in human hepatocytes (E hepatocytes,transporter ) and each double transfectant (E double,transporter ) by Western blot analyses and calculate the ratio of the expression level of each transporter in human hepatocytes to that in the double transfectant. Then, the biliary excretion clearance of ligands mediated by MRP2, MDR1, and BCRP in the human liver can be predicted as PS apical,transporter multiplied by the ratio of the protein expression level as described above.
Transporter-mediated drug-drug interactions and genetic polymorphisms of transporters
The possible transporters concerned with drug-drug interactions and genetic polymorphisms include: P-gp (efflux from brain and gastrointestinal epithelial cells, biliary and urinary excretion); OATP1B1, OATP1B3, OAT2, and OCT1 (hepatic uptake); OAT1, OAT3, and OCT2 (renal uptake); MRP2 (biliary and urinary excretion); MRP4 (urinary excretion); BCRP (efflux from brain and gastrointestinal epithelial cells, biliary and urinary excretion); MATE1,2 (biliary and urinary excretion); and peptide transporter 1 (PEPT1, gastrointestinal absorption) (Endres et al. 2006; Omote et al. 2006; Petzinger and Geyer 2006) .
In the United States, severe side effects such as rhabdomyolysis took place by the concomitant use of cerivastatin and cyclosporin A or gemfibrozil. Clinical studies have shown that plasma concentration and area under the plasma concentration-time curve (AUC) of cerivastatin are greatly increased in the presence of cyclosporin A or gemfibrozil (Muck et al. 1999; Backman et al. 2002) . We have shown that the interaction between cerivastatin and cyclosporin A involves the inhibition by cyclosporin A of the OATP1B1-mediated hepatic uptake of cerivastatin (Shitara et al. 2003) . The interaction between cerivastatin and gemfibrozil involves the inhibition by gemfibrozil glucuronide accumulated in the liver of the CYP2C8-mediated metabolism of cerivastatin (primary mechanism) and the inhibition by gemfibrozil glucuronide of the hepatic uptake of cerivastatin (secondary mechanism) (Shitara et al. 2004) (Fig. 9) . Recently, as with cerivastatin (substrates of CYP2C8, 3A4, and OATP1B1), some other drugs (e.g., atorvastatin, bosentan, and repaglinide) are known to be substrates of both transporters and metabolic enzymes. In such cases, although the major clearance mechanism of drugs is CYP-mediated metabolism in the liver, if drugs are substrates of hepatic uptake transporters and uptake process is the rate-limiting step of overall intrinsic hepatic clearance, the inhibition of uptake process by coadministered drugs greatly affected the overall clearance, while the inhibition of metabolism did not change it so much (Petzinger and Geyer 2006; . For example, Benet and colleagues have demonstrated that the clearance of atorvastatin, the dual substrate of OATP1B1 and CYP3A4, was greatly decreased by a single coadministration of rifampicin in humans (Lau et al. 2007 ). This interaction can be explained by the inhibition of the OATP1B1-mediated hepatic uptake of atorvastatin by rifampicin because the unbound plasma concentration of rifampicin is comparable to the IC 50 value of rifampicin for OATP1B1-mediated atorvastatin uptake and smaller than the IC 50 value of rifampicin for the CYP3A4-mediated metabolism (Lau et al. 2007 ). We are now developing a system for in silico quantitative prediction of drug-drug interactions with a large database of the pharmacokinetics of drugs, which can simulate the plasma and tissue concentration-time profile of drugs and predict the magnitude of the increase of plasma and tissue Fig. 10 The impact of haplotypes of OATP1B1 on the plasma concentration of pravastatin. a Two SNPs (N130D and V174A) are frequently observed in the OATP1B1 gene and their frequencies show some ethnic differences. In Japanese, the V174A mutation is usually linked to N130D and this allele is named as OATP1B1*15 (N130D +V174A). The right figure shows the location of the non-synonymous SNPs in OATP1B1 reported previously. b The plasma concentration of pravastatin after oral administration is significantly higher in subjects with the *15 allele of OATP1B1 compared with that of subjects with the *1b allele. c This result obtained from clinical study is consistent with the in vitro results in which the transport activities of E 2 17βG and estrone-3-sulfate normalized by their protein expression levels were significantly lower in OATP1B1*15-expressing cells compared with OATP1B1*1b-expressing cells. a is reproduced with permission from Tirona et al. (2001) , b is reproduced with permission from Nishizato et al. (2003) , and c is reproduced with permission from Iwai et al. (2004) Fig. 9 Elimination mechanism of cerivastatin in the liver and the target site of drug interaction between cerivastatin and cyclosporin A or gemfibrozil. In the human liver, cerivastatin is mainly taken up by OATP1B1 and metabolized by CYP2C8 (major) and CYP3A4 (minor) to metabolite M-1 and M-23. Cyclosporin A mainly inhibits the OATP1B1-mediated uptake of cerivastatin. Gemfibrozil glucuronide is highly concentrated in the liver and mainly inhibits the CYP2C8-mediated metabolism of cerivastatin concentration. This kind of system gives us the idea of drug-drug interaction without any clinical studies. Many genetic polymorphisms in genes encoding transporters have been found. Regarding the OATP1B1, we and other groups have demonstrated the effects of SNPs on the uptake clearance of OATP1B1 by using in vitro experimental systems expressing mutated OATP1B1 (Tirona et al. 2001; Iwai et al. 2004; Konig et al. 2006) . We have demonstrated the impact of SNPs in OATP1B1 on the pharmacokinetics of pravastatin in human clinical study for the first time and found that the plasma concentration of pravastatin in subjects with the OATP1B1*15 allele was significantly higher than that in subjects with OATP1B1*1b (Fig. 10) (Nishizato et al. 2003) . Recent clinical studies suggested that the pharmacokinetics of several OATP1B1 substrates has also been affected by the SNPs in OATP1B1 (Tirona et al. 2001; Niemi et al. 2005a Niemi et al. , b, 2006 Konig et al. 2006; Maeda et al. 2006; Zhang et al. 2007 ).
In the future, an analytical method must be established that allows the quantitative prediction of the pharmacokinetics of drugs in humans. Many outcomes of in vitro experiments with microsomes, hepatocytes, and transporters-and enzyme-expressing cells will be integrated to investigate the effect of drug interactions and functional changes by genetic polymorphism on the changes in the pharmacokinetics of drugs and to predict drug exposure in cells, tissues, and individual organisms (Fig. 11) .
Conclusion
Methods must be established to facilitate the prediction of drug exposure in various tissues (sites of drug efficacy and/ or adverse effect) from information on the pharmacokinetic properties of drugs and involvement of transporters and enzymes in its pharmacokinetics. A method that interrelates the pharmacological effects and pharmacokinetic information of different drugs in tissues is also required. Optimization of the pharmacokinetic properties of drugs allows the development of ideal drugs with fewer interindividual differences, fewer drug interactions, and selective delivery to target organs. We believe that it is possible to develop socalled blockbusters by optimizing the pharmacokinetic properties of drugs, even when the mechanisms of pharmacological action are the same as those of drugs already on the market. Fig. 11 Concept of the quantitative prediction of in vivo drug disposition in human subjects with genetic polymorphisms of enzymes and transporters. The methodology for the prediction of drug exposure in tissues (the sites of pharmacological actions and/or adverse effects) from information about the pharmacokinetic properties of drugs obtained from in vitro experiments. Clearance of wild type of metabolizing enzyme j (CL mj,wt ) and transporter l (CL tl,wt ) can be modified by the mutations in the patients' genes (mut#1, mut#2, mut#3). To predict the change in the total clearance in subjects with certain mutations in some genes of metabolic enzymes and transporters, the intrinsic clearance of mutated metabolic enzymes (CL mj,#n ) and transporters (CL tl,#n ) and that of the wild type (CL mj,wt , CL tl,wt ) can be observed from in vitro experimental systems. The contribution of each metabolic enzyme and transporter to the overall organ clearance in normal cases can also be estimated by using expression systems and human samples such as hepatocytes. Using these kinds of information, the intrinsic organ clearance in subjects with mutated enzymes and transporters can be expressed as a function of CL mj,#n and CL tl,#n . Then, hepatic (CL H ) and renal clearance (CL R ) can be calculated and the total clearance (CL tot ) can be predicted. The same concept of the integration of intrinsic parameters into the in vivo system can also be applied to the prediction of the change in the total clearance by drug-drug interactions or pathophysiological conditions
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